References

Azacitidine and venetoclax in previously untreated acute myeloid leukemia

10.1056/nejmoa2012971 · 2020 · External reference

Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia

10.1002/ajh.27246 · 2024 · External reference

Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML

10.1182/blood.2024027217 · 2025 · External reference

Results from paradigm-a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia

10.1182/blood-2025-6 · 2025 · External reference

Mayo genetic risk models for newly diagnosed acute myeloid leukemia treated with venetoclax+ hypomethylating agent

10.1002/ajh.27564 · 2025 · External reference

Impact of F LT3 mutation on outcomes after venetoclax and azacitidine for patients with treatment-naive acute myeloid leukemia

10.1158/1078-0432.ccr-21-3405 · 2022 · External reference

Genomic classification and prognosis in acute myeloid leukemia

10.1056/nejmoa1516192 · 2016 · External reference

Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia

10.1182/bloodadvances.2022009010 · 2023 · External reference

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

10.1182/blood.2024024944 · 2024 · External reference

Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML

10.1056/nejmoa1716984 · 2018 · External reference

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

10.1182/blood-2017-04-779405 · 2017 · External reference

Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML

10.1056/nejmoa1902688 · 2019 · External reference

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia

10.1038/s41586-023-05812-3 · 2023 · External reference

Outcomes of frontline triplet regimens with a hypomethylating agent, venetoclax, and isocitrate dehydrogenase inhibitor for intensive chemotherapy–ineligible patients with isocitrate dehydrogenase–mutated AML

10.1200/jco-25-00640 · 2025 · External reference

Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML

10.1182/bloodadvances.2025016399 · 2025 · External reference

Impact of venetoclax and azacitidine in treatment-naïve patients with acute myeloid leukemia and IDH1/2 mutations

10.1158/1078-0432.ccr-21-3467 · 2022 · External reference

Measurable residual disease response and prognosis in treatment-naïve acute myeloid leukemia with venetoclax and azacitidine

10.1200/jco.21.01546 · 2022 · External reference

Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-mutated AML

10.1200/jco.23.01911 · 2024 · External reference

Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial

10.1016/s0140-6736(23)00464-6 · 2023 · External reference

Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis

10.1001/jamaoncol.2020.4600 · 2020 · External reference

Venetoclax (VEN) and azacitidine (AZA) with gilteritinib (GILT) in patients with newly diagnosed (ND) FLT3mut+ Acute Myeloid Leukemia (AML) ineligible for intensive induction chemotherapy (chemo): interim results from the phase 1/2 VICEROY study

10.1182/blood-2025-654 · 2025 · External reference

Azacitidine, venetoclax, and revumenib for newly diagnosed NPM1-mutated or KMT2A-rearranged AML

10.1200/jco-25-00914 · 2025 · External reference

Phase II Study of the all-oral combination of revumenib (SNDX-5613) with decitabine/cedazuridine (ASTX727) and venetoclax (SAVE) in newly diagnosed AML

10.1182/blood-2025-47 · 2025 · External reference

A phase Ib/II study of ivosidenib with venetoclax±azacitidine in IDH1-mutated myeloid malignancies

10.1158/2643-3230.bcd-22-0205 · 2023 · External reference

Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML

10.1182/bloodadvances.2020001503 · 2020 · External reference

Genetic and Phenotypic correlates of clinical outcomes with Venetoclax in Acute Myeloid Leukemia: the GEN-PHEN-VEN study

10.1158/2643-3230.bcd-24-0256 · 2025 · External reference

Phase II study of venetoclax added to cladribine plus low-dose cytarabine alternating with 5-azacitidine in older patients with newly diagnosed acute myeloid leukemia

10.1200/jco.21.02823 · 2022 · External reference

Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy

10.1182/bloodadvances.2025017083 · 2025 · External reference

A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy

10.1158/2159-8290.cd-22-1297 · 2023 · External reference

Post-allogeneic hematopoietic cell transplantation outcomes are similar after hypomethylating agent/venetoclax and intensive, cytarabine-based remission induction for Acute Myeloid Leukemia when using standardized, contemporary transplant techniques

10.1182/blood-2025-44 · 2025 · External reference

Optimizing lower intensity triplet therapy in acute myeloid leukemia: a practical guide

10.1038/s41408-025-01429-z · 2025 · External reference